US panel endorses Roche's Avastin for brain cancer
This article was originally published in Scrip
Executive Summary
The US FDA's outside experts unanimously endorsed accelerated approval of Roche's (formerly Genentech) anti-VEGF monoclonal antibody Avastin (bevacizumab) in previously treated glioblastoma, finding the anticancer agent was reasonably likely to have a clinically meaningful benefit in this difficult to treat population.